News and Events

The HIV care landscape is constantly evolving, with breakthroughs in the methods, strategies and treatments to control and prevent transmission. This section aims to provide timely news updates and clinically relevant information about HIV disease management to clinicians who are actively involved in HIV care.

Upcoming events such as conferences, online seminars and continuing education programs will be listed here on a regular basis.

17th December 2019

The VOICE: HIV Clinical Research Training


The VOICE is a CPD-certified clinical research training programme organised and funded by Gilead Sciences Europe Ltd. The purpose of the programme is to help develop future HIV research leaders.

Register your interest

17th October 2019

What to expect at EACS 2019

In 2019, the 17th European AIDS Conference (EACS) will be held in Basel, Switzerland, from 6–9 November. The annual meeting attracts key audiences from across the HIV community and is instrumental in shaping the future of HIV science and medicine.

Gilead Sciences, a platinum sponsor for this year’s event, will be at the forefront of helping you translate new developments into daily clinical practice. Join us as we deliver multiple opportunities to participate in real-world, thought-provoking symposia, question leading researchers about new clinical data, and provide you with a unique space where you can meet, learn and share experiences with your peers.

Here’s a snapshot of what you can look forward to.

2nd September 2019

Beyond Undetectable: Going the full 360

Beyond Undetectable: Going the Full 360 brought together HIV specialists from across Europe to discuss and examine best practice in HIV care. The aim of the meeting was to consider progress towards achieving the UNAIDS 90-90-90 goals and set out a framework to move beyond viral-load to achieve the ‘fourth 90’ of life-long good health and wellbeing for people living with HIV (PLHIV).

On this site you can find additional educational materials from the meeting. We hope you find this content informative and impactful in improving care for PLHIV.

2nd July 2019

Findings from large systematic review may have implications for future ART guidelines

Results from a large systematic review of first-line combination antiretroviral therapy (ART) in people living with HIV (PLHIV) have confirmed that the type of nucleoside reverse transcriptase inhibitor (NRTI) backbone, type of third agent, and higher baseline CD4 lymphocyte counts, are independently predictive of greater efficacy at week 48.1

2nd July 2019

What’s it like to be living with HIV on treatment

All healthcare professionals understand that people living with HIV (PLHIV) present with an individual perspective of what it’s like to be on life-long antiretroviral therapy (ART). But what is it like to be living with HIV on an ART regimen? And would a person’s quality of life, daily functioning and other dimensions of health, be different if they were on a different regimen?

1st July 2019

PROs in practice: starting the conversation

As the clinical trial efficacy of contemporary antiretroviral regimens consistently exceed 90%, the impact of therapy on an individual’s overall health, including sense of wellbeing, has become an important consideration for clinicians when prescribing HIV treatment.1

27th June 2019

Almost 30% of PLHIV needed to stop initial ART regimen within 3 years, says new review

New data from almost 78,000 people enrolled in first-line HIV studies between 1994 and 2017, suggests that almost 30% needed to stop or change their initial ART regimen within 3 years. The authors note that while efficacy has improved over time, even with INSTI-based therapy, there is still a need to stop or change initial ART regimens within the first 3 years of treatment.1

25th June 2019

HIV 1994 to 2017: How far have we come?

A new analysis of outcomes in almost 78,000 people living with HIV (PLHIV), shows that the efficacy of first-line antiretroviral therapy (ART) continues to improve. However, the findings also highlight that phase 3 studies overestimate ‘real world efficacy’ and longer phase 4 studies in both resource-rich and resource-limited settings are required.1